DNA Methylation Changes in Ovarian Cancer
Author Information
Author(s): Watts George S, Futscher Bernard W, Holtan Nicholas, DeGeest Koen, Domann Frederick E, Rose Stephen L
Primary Institution: University of Arizona
Hypothesis
Can DNA methylation profiles differentiate between normal, low malignant potential, and stage III ovarian cancer samples?
Conclusion
Changes in CpG methylation are cumulative with ovarian cancer progression and can help identify affected genes.
Supporting Evidence
- 659 CpG islands showed significant loss or gain of methylation.
- The classifier developed had 87% sensitivity and 100% specificity on an independent test set.
- Bisulfite sequencing confirmed hypermethylation of the NKX-2-3 promoter with disease progression.
- 5-aza-2'-deoxycytidine treatment re-expressed NKX-2-3 in ovarian cancer cell lines.
Takeaway
This study looked at how DNA changes in ovarian cancer can help tell how advanced the cancer is, which might help doctors find it earlier.
Methodology
Analyzed methylation of 6,502 CpG-rich sequences in 137 ovarian samples using a microarray.
Potential Biases
Potential bias in sample selection as all tumor samples were taken from patients with no prior chemotherapy.
Limitations
The study primarily focused on late-stage ovarian cancer, which may limit the applicability of findings to early-stage detection.
Participant Demographics
137 ovarian samples (10 normal, 23 low malignant potential, 18 stage I, 16 stage II, 54 stage III, and 16 stage IV).
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website